Mark L. McCleland
Genentech · 137 works · 12,461 citations · h-index 40
Top works
- Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
- Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
- Inhibition of Aurora B Kinase Blocks Chromosome Segregation, Overrides the Spindle Checkpoint, and Perturbs Microtubule Dynamics in Mitosis
- Aurora B Kinase Exists in a Complex with Survivin and INCENP and Its Kinase Activity Is Stimulated by Survivin Binding and Phosphorylation
- Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
- The highly conserved Ndc80 complex is required for kinetochore assembly, chromosome congression, and spindle checkpoint activity
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
- Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
- The Vertebrate Ndc80 Complex Contains Spc24 and Spc25 Homologs, which Are Required to Establish and Maintain Kinetochore-Microtubule Attachment
- Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX
- IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
- USP7 small-molecule inhibitors interfere with ubiquitin binding
- Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
- MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC
- CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
- An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer
- IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).